According to Jefferies, Nuvalent could be a successful biotech in the world of cancer treatment. Analyst Roger Song initiated the clinical-stage biopharmaceutical company with a buy rating and a $97 price target, implying 49.8% upside potential for the stock over 12 months. next. “NUVL leverages strong expertise in structure-based chemistry and a deep understanding of unmet problems [patient] need to develop potentially 'best-in-class' small-molecule targeted cancer therapies,” Song wrote in a note Wednesday. Food and Drug Administration, analyst said US products granted the company breakthrough therapy designation on February 27 for the treatment of small cell lung cancer, or NSCLC, as well as “impressive” data showing high efficacy and tolerability. good in later drug lines. patients with ROS1-positive NSCLC or ALK+ NSCLC who have been previously treated with two or more ROS1 tyrosine kinase inhibitors in NSCLC, which differentiates it from approved pipeline drugs,” Song said. The candidates are well-poised downstream and have strong potential to move into frontline treatments.” The analyst estimates Nuvalent's platform and pipeline is worth $300 million. He estimates approximately $1.7 billion in US highest probability adjusted Zidesamtinib sales for ROS1+ NSCLC and approximately $2.6 billion in US highest probability adjusted NVL-655 sales in ALK + NSCLC. This year, Nuvalent shares have lost 12.8%. The company reported a slightly larger-than-expected fourth-quarter loss of 62 cents per share. Analysts polled by FactSet forecast a loss of 60 cents per share. Nuvalent's research and development costs were $35.6 million in the period, $3.9 million more than analysts expected, but Jefferies noted that the company had about 720 million USD in cash, which will fund the company's operations until 2027.